DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma

Augusto Villanueva, Anna Portela, Sergi Sayols, Carlo Battiston, Yujin Hoshida, Jesús Méndez-González, Sandrine Imbeaud, Eric Letouzé, Virginia Hernandez-Gea, Helena Cornella, Roser Pinyol, Manel Solé, Josep Fuster, Jessica Zucman-Rossi, Vincenzo Mazzaferro, Manel Esteller, Josep M. Llovet

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Epigenetic deregulation has emerged as a driver in human malignancies. There is no clear understanding of the epigenetic alterations in hepatocellular carcinoma (HCC) and of the potential role of DNA methylation markers as prognostic biomarkers. Analysis of tumor tissue from 304 patients with HCC treated with surgical resection allowed us to generate a methylation-based prognostic signature using a training-validation scheme. Methylome profiling was done with the Illumina HumanMethylation450 array (Illumina, Inc., San Diego, CA), which covers 96% of known cytosine-phosphate-guanine (CpG) islands and 485,000 CpG, and transcriptome profiling was performed with Affymetrix Human Genome U219 Plate (Affymetrix, Inc., Santa Clara, CA) and miRNA Chip 2.0. Random survival forests enabled us to generate a methylation signature based on 36 methylation probes. We computed a risk score of mortality for each individual that accurately discriminated patient survival both in the training (221 patients; 47% hepatitis C-related HCC) and validation sets (n=83; 47% alcohol-related HCC). This signature correlated with known predictors of poor outcome and retained independent prognostic capacity of survival along with multinodularity and platelet count. The subset of patients identified by this signature was enriched in the molecular subclass of proliferation with progenitor cell features. The study confirmed a high prevalence of genes known to be deregulated by aberrant methylation in HCC (e.g., Ras association [RalGDS/AF-6] domain family member 1, insulin-like growth factor 2, and adenomatous polyposis coli) and other solid tumors (e.g., NOTCH3) and describes potential candidate epidrivers (e.g., septin 9 and ephrin B2). Conclusions: A validated signature of 36 DNA methylation markers accurately predicts poor survival in patients with HCC. Patients with this methylation profile harbor messenger RNA-based signatures indicating tumors with progenitor cell features.

Original languageEnglish
Pages (from-to)1945-1956
Number of pages12
JournalHepatology
Volume61
Issue number6
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

DNA Methylation
Hepatocellular Carcinoma
Methylation
Survival
Cytosine
Guanine
Genetic Markers
Epigenomics
Neoplasms
Ephrin-B2
Stem Cells
Septins
Phosphates
Adenomatous Polyposis Coli
Gene Expression Profiling
Somatomedins
Human Genome
Hepatitis C
MicroRNAs
Platelet Count

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Cite this

Villanueva, A., Portela, A., Sayols, S., Battiston, C., Hoshida, Y., Méndez-González, J., ... Llovet, J. M. (2015). DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology, 61(6), 1945-1956. https://doi.org/10.1002/hep.27732

DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. / Villanueva, Augusto; Portela, Anna; Sayols, Sergi; Battiston, Carlo; Hoshida, Yujin; Méndez-González, Jesús; Imbeaud, Sandrine; Letouzé, Eric; Hernandez-Gea, Virginia; Cornella, Helena; Pinyol, Roser; Solé, Manel; Fuster, Josep; Zucman-Rossi, Jessica; Mazzaferro, Vincenzo; Esteller, Manel; Llovet, Josep M.

In: Hepatology, Vol. 61, No. 6, 01.06.2015, p. 1945-1956.

Research output: Contribution to journalArticle

Villanueva, A, Portela, A, Sayols, S, Battiston, C, Hoshida, Y, Méndez-González, J, Imbeaud, S, Letouzé, E, Hernandez-Gea, V, Cornella, H, Pinyol, R, Solé, M, Fuster, J, Zucman-Rossi, J, Mazzaferro, V, Esteller, M & Llovet, JM 2015, 'DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma', Hepatology, vol. 61, no. 6, pp. 1945-1956. https://doi.org/10.1002/hep.27732
Villanueva A, Portela A, Sayols S, Battiston C, Hoshida Y, Méndez-González J et al. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology. 2015 Jun 1;61(6):1945-1956. https://doi.org/10.1002/hep.27732
Villanueva, Augusto ; Portela, Anna ; Sayols, Sergi ; Battiston, Carlo ; Hoshida, Yujin ; Méndez-González, Jesús ; Imbeaud, Sandrine ; Letouzé, Eric ; Hernandez-Gea, Virginia ; Cornella, Helena ; Pinyol, Roser ; Solé, Manel ; Fuster, Josep ; Zucman-Rossi, Jessica ; Mazzaferro, Vincenzo ; Esteller, Manel ; Llovet, Josep M. / DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. In: Hepatology. 2015 ; Vol. 61, No. 6. pp. 1945-1956.
@article{491c0589da014a3d9bd98ca894132428,
title = "DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma",
abstract = "Epigenetic deregulation has emerged as a driver in human malignancies. There is no clear understanding of the epigenetic alterations in hepatocellular carcinoma (HCC) and of the potential role of DNA methylation markers as prognostic biomarkers. Analysis of tumor tissue from 304 patients with HCC treated with surgical resection allowed us to generate a methylation-based prognostic signature using a training-validation scheme. Methylome profiling was done with the Illumina HumanMethylation450 array (Illumina, Inc., San Diego, CA), which covers 96{\%} of known cytosine-phosphate-guanine (CpG) islands and 485,000 CpG, and transcriptome profiling was performed with Affymetrix Human Genome U219 Plate (Affymetrix, Inc., Santa Clara, CA) and miRNA Chip 2.0. Random survival forests enabled us to generate a methylation signature based on 36 methylation probes. We computed a risk score of mortality for each individual that accurately discriminated patient survival both in the training (221 patients; 47{\%} hepatitis C-related HCC) and validation sets (n=83; 47{\%} alcohol-related HCC). This signature correlated with known predictors of poor outcome and retained independent prognostic capacity of survival along with multinodularity and platelet count. The subset of patients identified by this signature was enriched in the molecular subclass of proliferation with progenitor cell features. The study confirmed a high prevalence of genes known to be deregulated by aberrant methylation in HCC (e.g., Ras association [RalGDS/AF-6] domain family member 1, insulin-like growth factor 2, and adenomatous polyposis coli) and other solid tumors (e.g., NOTCH3) and describes potential candidate epidrivers (e.g., septin 9 and ephrin B2). Conclusions: A validated signature of 36 DNA methylation markers accurately predicts poor survival in patients with HCC. Patients with this methylation profile harbor messenger RNA-based signatures indicating tumors with progenitor cell features.",
author = "Augusto Villanueva and Anna Portela and Sergi Sayols and Carlo Battiston and Yujin Hoshida and Jes{\'u}s M{\'e}ndez-Gonz{\'a}lez and Sandrine Imbeaud and Eric Letouz{\'e} and Virginia Hernandez-Gea and Helena Cornella and Roser Pinyol and Manel Sol{\'e} and Josep Fuster and Jessica Zucman-Rossi and Vincenzo Mazzaferro and Manel Esteller and Llovet, {Josep M.}",
year = "2015",
month = "6",
day = "1",
doi = "10.1002/hep.27732",
language = "English",
volume = "61",
pages = "1945--1956",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma

AU - Villanueva, Augusto

AU - Portela, Anna

AU - Sayols, Sergi

AU - Battiston, Carlo

AU - Hoshida, Yujin

AU - Méndez-González, Jesús

AU - Imbeaud, Sandrine

AU - Letouzé, Eric

AU - Hernandez-Gea, Virginia

AU - Cornella, Helena

AU - Pinyol, Roser

AU - Solé, Manel

AU - Fuster, Josep

AU - Zucman-Rossi, Jessica

AU - Mazzaferro, Vincenzo

AU - Esteller, Manel

AU - Llovet, Josep M.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Epigenetic deregulation has emerged as a driver in human malignancies. There is no clear understanding of the epigenetic alterations in hepatocellular carcinoma (HCC) and of the potential role of DNA methylation markers as prognostic biomarkers. Analysis of tumor tissue from 304 patients with HCC treated with surgical resection allowed us to generate a methylation-based prognostic signature using a training-validation scheme. Methylome profiling was done with the Illumina HumanMethylation450 array (Illumina, Inc., San Diego, CA), which covers 96% of known cytosine-phosphate-guanine (CpG) islands and 485,000 CpG, and transcriptome profiling was performed with Affymetrix Human Genome U219 Plate (Affymetrix, Inc., Santa Clara, CA) and miRNA Chip 2.0. Random survival forests enabled us to generate a methylation signature based on 36 methylation probes. We computed a risk score of mortality for each individual that accurately discriminated patient survival both in the training (221 patients; 47% hepatitis C-related HCC) and validation sets (n=83; 47% alcohol-related HCC). This signature correlated with known predictors of poor outcome and retained independent prognostic capacity of survival along with multinodularity and platelet count. The subset of patients identified by this signature was enriched in the molecular subclass of proliferation with progenitor cell features. The study confirmed a high prevalence of genes known to be deregulated by aberrant methylation in HCC (e.g., Ras association [RalGDS/AF-6] domain family member 1, insulin-like growth factor 2, and adenomatous polyposis coli) and other solid tumors (e.g., NOTCH3) and describes potential candidate epidrivers (e.g., septin 9 and ephrin B2). Conclusions: A validated signature of 36 DNA methylation markers accurately predicts poor survival in patients with HCC. Patients with this methylation profile harbor messenger RNA-based signatures indicating tumors with progenitor cell features.

AB - Epigenetic deregulation has emerged as a driver in human malignancies. There is no clear understanding of the epigenetic alterations in hepatocellular carcinoma (HCC) and of the potential role of DNA methylation markers as prognostic biomarkers. Analysis of tumor tissue from 304 patients with HCC treated with surgical resection allowed us to generate a methylation-based prognostic signature using a training-validation scheme. Methylome profiling was done with the Illumina HumanMethylation450 array (Illumina, Inc., San Diego, CA), which covers 96% of known cytosine-phosphate-guanine (CpG) islands and 485,000 CpG, and transcriptome profiling was performed with Affymetrix Human Genome U219 Plate (Affymetrix, Inc., Santa Clara, CA) and miRNA Chip 2.0. Random survival forests enabled us to generate a methylation signature based on 36 methylation probes. We computed a risk score of mortality for each individual that accurately discriminated patient survival both in the training (221 patients; 47% hepatitis C-related HCC) and validation sets (n=83; 47% alcohol-related HCC). This signature correlated with known predictors of poor outcome and retained independent prognostic capacity of survival along with multinodularity and platelet count. The subset of patients identified by this signature was enriched in the molecular subclass of proliferation with progenitor cell features. The study confirmed a high prevalence of genes known to be deregulated by aberrant methylation in HCC (e.g., Ras association [RalGDS/AF-6] domain family member 1, insulin-like growth factor 2, and adenomatous polyposis coli) and other solid tumors (e.g., NOTCH3) and describes potential candidate epidrivers (e.g., septin 9 and ephrin B2). Conclusions: A validated signature of 36 DNA methylation markers accurately predicts poor survival in patients with HCC. Patients with this methylation profile harbor messenger RNA-based signatures indicating tumors with progenitor cell features.

UR - http://www.scopus.com/inward/record.url?scp=84929606441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929606441&partnerID=8YFLogxK

U2 - 10.1002/hep.27732

DO - 10.1002/hep.27732

M3 - Article

C2 - 25645722

AN - SCOPUS:84929606441

VL - 61

SP - 1945

EP - 1956

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 6

ER -